International Assets Investment Management LLC Makes New Investment in Progyny, Inc. $PGNY

International Assets Investment Management LLC purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY) during the second quarter, Holdings Channel reports. The firm purchased 154,464 shares of the company’s stock, valued at approximately $3,398,000.

A number of other hedge funds also recently bought and sold shares of the business. Millennium Management LLC boosted its position in Progyny by 7.5% during the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock worth $29,107,000 after purchasing an additional 90,367 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Progyny by 8.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 689,443 shares of the company’s stock worth $15,402,000 after purchasing an additional 51,810 shares in the last quarter. Wellington Management Group LLP boosted its position in Progyny by 67.7% during the first quarter. Wellington Management Group LLP now owns 660,982 shares of the company’s stock worth $14,766,000 after purchasing an additional 266,853 shares in the last quarter. Nuveen LLC purchased a new position in shares of Progyny in the first quarter valued at approximately $13,645,000. Finally, CenterBook Partners LP lifted its position in shares of Progyny by 458.2% in the first quarter. CenterBook Partners LP now owns 515,626 shares of the company’s stock valued at $11,519,000 after acquiring an additional 423,257 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Buying and Selling at Progyny

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the sale, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,895 shares of company stock valued at $179,311. 9.40% of the stock is owned by insiders.

Progyny Stock Performance

NASDAQ:PGNY opened at $19.34 on Friday. Progyny, Inc. has a one year low of $13.39 and a one year high of $26.76. The stock has a market cap of $1.66 billion, a PE ratio of 32.78, a P/E/G ratio of 1.64 and a beta of 1.34. The stock has a 50 day moving average price of $22.02 and a 200 day moving average price of $22.13.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same period in the prior year, the business posted $0.17 EPS. Progyny’s revenue for the quarter was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. Finally, Raymond James Financial set a $28.00 target price on Progyny in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Progyny has an average rating of “Moderate Buy” and an average target price of $25.44.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.